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Conclusion: Both SBRT and VMAT treatments were highly 
successful in terms of PSA control. QOL assessment were 
found to be mostly similar between treatment modalities. 
Grade 3 urinary toxicities might be eliminated with careful 
patient selection for SBRT technique 
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Purpose or Objective: The aim of this work is to develop an 
algorithm to predict recurrence in prostate cancer patients 
treated with radical radiotherapy, getting up to a prognostic 
power higher than traditional D'Amico risk classification.  
 
Material and Methods: 2493 men belonging to the EUREKA-2 
retrospective multi-centric database on prostate cancer and 
treated with external-beam radiotherapy (3D-CRT and or 
IMRT) as primary treatment comprised the study population. 
A Cox regression time to PSA failure analysis was performed 
in univariate and multivariate settings, evaluating the 
predictive ability of age, pre-treatment PSA, clinical-
radiological staging, Gleason score and percentage of positive 
cores at biopsy (%PC). The accuracy of this model was 
checked with bootstrapping statistics. Subgroups for all the 
variables' combinations were combined to classify patients 
into five different "Candiolo" risk-classes for biochemical 
Progression Free Survival (bPFS); thereafter, they were also 
applied to clinical PFS (cPFS), systemic PFS (sPFS) and 
Prostate Cancer Specific Survival (PCSS), and compared to 
D'Amico risk grouping performances.  
 
Results: the Candiolo classifier splits patients in 5 risk-groups 
with the following 10-years bPFS, cPFS, sPFS and PCSS: for 
very-low-risk 90%, 94%, 100% and 100%; for low-risk 74%, 88%, 
94% and 98%; for intermediate-risk 60%, 82%, 91% and 92%; 
for high-risk 43%, 55%, 80% and 89% and for very-high-risk 
14%, 38%, 56% and 70%. Our classifier outperforms D'Amico 
risk classes for all the end-points evaluated, with 
concordance indexes of 71.5%, 75.5%, 80% and 80.5% versus 
63%, 65.5%, 69.5% and 69%, respectively.  
 
Conclusion: Our classification tool, combining five clinical 
and easily available parameters, seems to better stratify 
patients in predicting prostate cancer recurrence after 
radiotherapy compared to the traditional D'Amico risk 
classes. This classifier must be validate by another prostate 
cancer series.  
References: Gabriele D et al: Beyond D'Amico risk classes for 
predicting recurrence after external beam radiotherapy for 
prostate cancer: the Candiolo classifier. Radiat Oncol 2015, 
in press 
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Purpose or Objective: To test the hypothesis that 
rectal/bladder preparation is associated with an increase in 
Cancer Specific Overall Survival (CSOS), in Clinical Disease 
Free (CDFS) and Biochemical Disease free Survival (BDFS) 
 
Material and Methods: From October 1999 to March 2012, 
1080 prostate cancer patients (PCa) were treated with 
3DCRT. 761 patients (pts) were treated with empty rectum 
and comfortable full bladder while for 319 pts no 
rectal/bladder preparation (NRBP) protocol was adopted. The 
mean age was 69.2±5.6 years. The mean prescribed dose was 
76±2 Gy. The mean followup was 81±39 months. Survival 
analysis was performed by Kaplan Meier method. Comparison 
between groups were made with the log–rank test. A Cox 
proportional hazards model was applied for univariate (UVA) 
and multivariate analysis (MVA). Hazard Ratio (HR) was used 
to measure how rapidly an event occurs. 
 
Results: Pts with rectal/bladder preparation (RBP) have 
significantly lower biochemical and clinical failures rates and 
lower risk of dying of PCa respect to NRBP pts (log-rank 
p<0.0001). At 140 months for RBP and NRPB, the CSOS was 
95% vs 85%, the CDFS was 81% vs 71%, the BDFS was 64% vs 48 
%, respectively. Table 1 shows UVA and MVA results. In MVA, 
for CSOS the Gleason Score (GS) and RBP predicted for death 
from PCa, while for CDSF and BDFS the GS, D’Amico Risk 
Classification, PSA, dose>75 Gy, clinical stage and RBP 
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predicted for clinical and biochemical failures. MVA indicates 
that RBP is an independent risk factor for biochemical failure 
(p=0.003, HR=0.6) while it is the strongest risk factor for 
clinical failures and PCa deaths (p<0.0001, HR<0.5, regression 
coefficient b<-0.5). No statistical significant difference in 
rectal volume between RBP (mean volume 62.4±24.5 cc) and 
NRPB (mean volume 63.4±27 cc) was observed (chi square p 
value equal to 0.52) 
 
 
 
Conclusion: We found strong evidence that rectal/bladder 
preparation significantly decreased (HR<0.6, b<-0.5) the 
probability of death from PCa, biochemical and clinical 
failures in patients who were treated with 3DCRT for PCa 
without daily image-guided prostate localization, presumably 
because pts with RBP are able to maintain a reproducible 
empty rectum and comfortable full bladder for all the 
treatment. These results also emphasize the routinely need 
of image-guided radiotherapy to improve outcome in prostate 
cancer patients 
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Purpose or Objective: The aim of the study is to 
prospectively evaluate urinary symptoms using the 
International Prostate Symptom Score (IPSS) in patients with 
localized prostate cancer (CaP) treated with radical (RRT) or 
postprostatectomy (PRT) radiotherapy delivered with 
conventional (CONV) or moderately hypofractionated (HYPO) 
fractionation. 
 
Material and Methods: We considered patients enrolled in 
the two multicentric prospective observational studies DUE01 
(RRT, CONV and HYPO) and IHU WPRT TOX (RRT and PRT, 
including irradiation of the pelvic lymphnodal area, CONV 
and HYPO). The IPSS questionnaire, evaluating 7 symptoms 
(IPSS1-IPSS7) and a quality of life (IPSS8), is filled in before 
and at the end of RT, then 3 and 6 after treatment end and 
every 6 months thereafter up to 5 years after the end of 
treatment. In this preliminary analysis only data relative to 
first year will be analyzed. Longitudinal trends were assessed 
by analysis of variance (anova). 
 
Results: The analysis pertains to 146 RRT CONV pts, 104 RRT 
HYPO pts, 74 PRT CONV pts and 94 PRT HYPO. The median 
age in the 2 studies was 71 (RRT) and 66 (PRT) years (p = 
0.0001). Overall, urinary function was always better in the 
RRT CONV cohort. Statistically significant differences among 
the 4 groups have emerged with respect to urinary 
frequency, urgency, effort, nocturia. When comparing RRT vs 
PRT, frequency (p = 0.007) and stress (p = 0.01) were 
significantly more present in PRT, while only a borderline 
difference in terms of urgency (p = 0.07) was evident. The 
last item of IPSS shows a significant difference of quality of 
life between groups, especially at 12 month where RRT 
cohort, especially CONV, shows a better score than PRT 
patients. Figure 1 shows the comparison of each group for all 
IPSS items (incomplete emptyng, urinary frequency, 
intermittence, urgency, urinary stream, obstruction, 
nocturia, QoL), evaluating the mean response in the first five 
time of compilation (Rt start, RT end, 3m, 6m, 12m). 
 
 
Conclusion: These preliminary results seem to suggest that 
RRT would result in less deterioration of urinary symptoms 
over time than PRT, especially RRT with conventional 
fractionation. Further analyses are ongoing in order to study 
the effect of baseline urinary situation, age, doses to the 
bladder and the impact of each urinary symptoms on quality 
of life.  
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